查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1922965

人腦模型市場：2026-2032年全球預測（依疾病模型、技術、應用和最終用戶分類）

Human Brain Models Market by Disease Model, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人腦模型市場價值將達到 2.1345 億美元，到 2026 年將成長至 2.4333 億美元，到 2032 年將達到 5.6782 億美元，複合年成長率為 15.00%。

關鍵市場統計數據
基準年 2025 2.1345億美元
預計年份：2026年 2.4333億美元
預測年份 2032 5.6782億美元
複合年成長率 (%) 15.00%

人腦模型技術作為轉化神經科學和治療發展的重要組成部分，其策略背景和必要性值得探討。

人腦模型如今在神經科學、生物技術和轉化醫學的交叉領域扮演核心角色，迫使各機構重新思考如何建構其臨床前研究和藥物發現流程。本文將此主題置於更廣泛的多學科領域背景下進行探討，該領域中組織工程、計算建模和微加工技術的進步正在催生新的實驗範式。本文旨在幫助讀者理解這些技術對藥物發現、神經機制研究、個人化醫療和安全性評估的戰略意義，並強調決策者為何必須對這些技術有深入的了解。

識別將重塑人腦模型研究和轉化整合的技術、制度和監管轉折點

人類腦模型研究領域正經歷著一場變革性的轉變，其驅動力包括技術的成熟、跨學科的融合以及相關人員期望的轉變。先進的生物製造和類器官培養等技術催化劑使得構建生理相關性更高的模型成為可能，而微流體系統和神經介面則提高了實驗控制的精確度和數據密度。同時，計算模擬模型透過提供可擴展的假設生成和整合分析，對濕實驗室系統起到了補充作用，從而構建了一個物理模型和虛擬模型共同演化的混合生態系統。

分析 2025 年引入關稅後供應鏈限制和政策因應措施對整個研究生態系統採購、合作和營運的系統性調整的影響。

2025年關稅及貿易政策調整對支持人腦模型研究的生態系統產生了多方面的影響。特殊試劑、生物材料、精密加工設備和微流體組件的供應鏈均受到不同程度的干擾，迫使採購團隊重新評估籌資策略。為此，各機構已開始評估替代供應商，盡可能在地採購，並調整庫存政策，以保護正在進行的研究免受突發中斷的影響。這些營運應對措施已成為業務永續營運計畫的重要組成部分。

整合按模型類型、應用領域、最終用戶、技術和疾病模型分類的細分，以製定有針對性的開發和轉化研究的優先策略。

透過辨識技術能力與使用者需求的交集，可以建構更精細的細分框架，從而實現更精確的策略規劃。基於模型類型，該領域涵蓋：3D列印結構（包括基於生物墨水的模型）；動物模型（涵蓋豬、靈長類動物和囓齒類動物系統）；計算模型（In Silico模型）；幹細胞衍生系統（包括胚胎幹細胞、誘導多能幹細胞和神經幹細胞平台）；以及涵蓋微流體和類器官相容形式的合成結構。每類模型都有其自身的檢驗挑戰和價值提案。使用生物墨水的3D列印組織強調結構保真度和擴充性，而動物模型則提供了成熟的生理複雜性，可用於物種間比較。In Silico模型能夠快速探索參數和建構機制假設，而幹細胞平台則能夠展現不同成熟階段的人類細胞的相關性。最後，合成微流體和類器官系統將可控性與獨特的人類生物學特性結合。

識別區域優勢、監管差異和創新生態系統將決定全球市場的策略切入點和合作路徑。

區域動態是策略定位的核心，因為不同地區的創新生態系統、法規環境和生產能力差異顯著。在美洲，強大的轉化研究基礎、密集的臨床試驗中心網路以及成熟的生物技術資金籌措環境，支持了從發現到早期臨床檢驗的快速進展。該地區還擁有成熟的生物製造能力和豐富的經驗豐富的神經科學家人才儲備，這些優勢共同促進了產業界和學術界相關人員之間的夥伴關係，並推動了原型平台向檢驗服務的規模化轉化。

評估決定空間領導地位和擴充性的競爭策略、平台差異化、夥伴關係模式和創新策略

在人腦模型領域，各公司之間的競爭動態集中在平台差異化、服務廣度以及透過檢驗研究和外部合作來證明其轉化應用價值的能力。主要企業強調模組化平台，讓客戶可以根據疾病重點、分析輸出和通量來配置模型，從而滿足學術界和商業用戶多樣化的研究需求。與學術機構和臨床聯盟建立策略夥伴關係，是提升信譽度並實現平台表現與既定生物學終點指標對標的重要手段。

實施穩健的採購流程、協同檢驗、模組化產品架構和多學科人才策略，以加速產品推廣應用並降低開發風險。

領導者應採取一系列切實可行的措施，使技術能力與組織目標和市場實際情況保持一致。首先，應優先考慮供應鏈韌性，具體措施包括：為關鍵試劑和組件建立雙源籌資策略、選擇區域供應商以及建立緊急庫存，以最大限度地減少中斷。這種戰術性轉變將降低營運風險，並即使在面臨外部衝擊的情況下，也能維持研發進度的可預測性。

我們將展示一種嚴謹的混合調查方法，該方法整合了專家訪談、文獻和專利研究、技術準備評估和檢驗研討會。

本分析的調查方法結合了定性和定量方法，以確保其穩健性和實用性。主要研究包括對各類利害關係人進行結構化訪談，其中包括資深學術研究人員、製藥和生物技術公司的研發總監、專業合約研究機構的負責人、醫療器材開發人員和監管相關人員。這些訪談從多個觀點深入探討了技術採納的促進因素、檢驗要求和採購時間表。

整合策略要務和營運重點，以確定哪些組織能夠將人腦模型創新轉化為永續的臨床和商業性價值。

總之，人腦模型是一套變革性的工具，正在重塑神經科學解決問題的方式，並在臨床開發前降低治療策略的風險。該領域的特點是技術快速融合、監管要求不斷演變以及商業模式的轉變，這些都旨在評估可證實的轉化相關性。投資於檢驗、互通性和供應鏈韌性的相關人員將更有利於把平台進步轉化為具有臨床意義的成果。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依疾病模型分類的人腦模型市場

  • 阿茲海默症
  • 癲癇
  • 帕金森氏症
  • 中風

9. 按技術分類的人腦模型市場

  • 生物製造
  • 微流體技術
    • 液滴微流體技術
    • 器官晶片
  • 神經介面
    • 體外電生理學
    • 體內記錄
  • 類器官培養
    • 鷹架底座
    • 無支架

第10章 人類腦模型市場依應用領域分類

  • 藥物發現
    • 高通量篩檢
    • 先導藥物最適化
  • 神經科學研究
    • 阿茲海默症研究
    • 帕金森氏症調查
    • 中風研究
  • 個人化醫療
  • 毒性測試

第11章 以最終用戶分類的人腦模型市場

  • 學術機構
    • 研究所
    • 大學
  • CRO（受託研究機構）
  • 醫院和診所
  • 製藥和生物技術公司
    • 大型製藥企業
    • 中小型生技公司

第12章 人類大腦模型市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 人類腦模型市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國人腦模型市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國人類大腦模型市場

第16章 中國的人腦模型市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3D Systems, Inc.
  • Anatomy Warehouse, LLC
  • Brainlab AG
  • EISCO Scientific
  • ESP Models
  • GE HealthCare Technologies Inc.
  • Global Plastics, Inc.
  • GPI Anatomicals
  • Koninklijke Philips NV
  • Materialise NV
  • Medtronic plc
  • Organovo Holdings, Inc.
  • Scientific Accessories, Inc.
  • Siemens Healthineers AG
  • SmartLabs Education Ltd.
  • Stratasys Ltd.
  • Stryker Corporation
Product Code: MRR-867BED9A9E8A

The Human Brain Models Market was valued at USD 213.45 million in 2025 and is projected to grow to USD 243.33 million in 2026, with a CAGR of 15.00%, reaching USD 567.82 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 213.45 million
Estimated Year [2026] USD 243.33 million
Forecast Year [2032] USD 567.82 million
CAGR (%) 15.00%

Establishing strategic context and imperatives for human brain model technologies as indispensable components of translational neuroscience and therapeutic development

Human brain models now occupy a central role at the intersection of neuroscience, biotechnology, and translational medicine, prompting organizations to reassess how preclinical and discovery pipelines are constructed. This introduction positions the topic within a broader context of converging disciplines where advances in tissue engineering, computational modeling, and microfabrication are enabling new experimental paradigms. The intent here is to orient readers to the strategic relevance of these technologies for drug discovery, mechanistic neuroscience, personalized medicine, and safety assessment, emphasizing why a refined understanding is essential for decision-makers.

Across institutions and commercial entities, the impetus to adopt complex human-relevant systems has shifted from academic curiosity to operational necessity. Researchers and R&D leaders face mounting pressure to reduce late-stage failure, accelerate translational fidelity, and meet increasingly stringent ethical and regulatory expectations. Consequently, the adoption of human brain models is driven by scientific imperatives and institutional risk management, with significant implications for platform selection, partnership formation, and investment prioritization.

As we progress through this executive summary, readers will encounter a synthesis of technological trends, segmentation dynamics, regional attributes, and tactical recommendations. The following sections are designed to provide a compact yet substantive foundation for executives and technical leaders who must align organizational strategy to a rapidly evolving research landscape, while also anticipating regulatory and supply chain shifts that influence adoption trajectories.

Identifying pivotal technological, institutional, and regulatory inflection points reshaping human brain model research and translational integration

The landscape for human brain models is undergoing transformative shifts driven by technological maturation, interdisciplinary integration, and evolving stakeholder expectations. Technological catalysts such as advanced biofabrication and organoid culture are enabling increasingly physiologically relevant constructs, while microfluidic systems and neural interfaces are improving experimental control and data density. Concurrently, computational in silico models complement wet-lab systems by providing scalable hypothesis generation and integrative analyses, creating a hybrid ecosystem where physical and virtual models co-evolve.

Institutional behavior is adapting to these capabilities. Academic laboratories are forming translational consortia with industry partners to accelerate validation and standardization, and contract research organizations are expanding service portfolios to include model development and qualification services. Funding bodies and private investors have reoriented priorities toward platforms that promise higher translational fidelity, with an emphasis on human-relevant endpoints. These shifts are reinforcing a move away from single-model reliance toward diversified model stacks tailored to specific research questions.

Regulatory and ethical considerations are also reshaping the field. Guidance frameworks and ethics discourse now prioritize reproducibility, data transparency, and humane research practices, incentivizing the adoption of validated alternatives to traditional animal testing. As a result, organizations that proactively align technology development with regulatory expectations and ethical standards gain first-mover advantages in collaboration, market access, and stakeholder trust. Taken together, these transformative shifts underscore a trajectory in which integration, validation, and interoperability become the primary determinants of long-term impact.

Analyzing how 2025 tariff-driven supply chain constraints and policy responses are prompting systemic procurement, partnership, and operational adjustments across the research ecosystem

The imposition of tariffs and trade policy adjustments in 2025 has produced multifaceted effects on the ecosystem that supports human brain model research. Supply chains for specialized reagents, raw biomaterials, precision fabrication equipment, and microfluidic components have been disrupted in varying degrees, prompting procurement teams to reassess sourcing strategies. In response, organizations have begun to evaluate alternative suppliers, localize critical inputs where feasible, and adjust inventory policies to insulate ongoing research from episodic disruptions. These operational responses have become integral to continuity planning.

Secondary effects are visible in the structure of commercial partnerships and procurement frameworks. International collaborators are negotiating new terms to accommodate customs complexity, delayed lead times, and the administrative burden of cross-border shipments. Consequently, some consortia have shifted toward onshore manufacturing or regional distribution hubs to reduce exposure to customs volatility. While these adaptations enhance resilience, they also necessitate upfront investment in qualification and vendor audits, altering cost and timeline calculations for model development projects.

Furthermore, policy shifts have influenced strategic decisions around technology transfer and intellectual property management. Entities pursuing collaborative research are placing greater emphasis on contractual clarity related to responsibilities for export compliance and tariff-related contingencies. This has led to more conservative timelines for multicenter validations and a preference for modular project designs that can tolerate phased component deliveries. Collectively, these dynamics are shaping how organizations prioritize projects, select suppliers, and structure international collaborations within the human brain model ecosystem.

Integrating model type, application, end-user, technology, and disease-model segmentation to inform targeted development and translational prioritization strategies

A nuanced segmentation framework reveals where technological capability and user need intersect, enabling more precise strategic planning. Based on model type, the field encompasses 3D printed constructs that include bioink-based approaches, animal models spanning porcine, primate, and rodent systems, computational or in silico models, stem cell-derived systems comprising embryonic stem cell, induced pluripotent stem cell, and neural stem cell platforms, and synthetic constructs that cover microfluidic and organoid-enabled formats. Each model class presents distinct validation challenges and value propositions: bioink-based 3D printed tissues emphasize architectural fidelity and scalability; animal models offer established physiological complexity for cross-species comparison; in silico models provide rapid parameter sweeps and mechanistic hypotheses; stem cell platforms deliver human cellular relevance with varying maturation states; and synthetic microfluidic and organoid systems bridge control with human-specific biology.

Application segmentation further clarifies demand patterns, with drug discovery activities driven by high throughput screening and lead optimization, neuroscience research targeted at Alzheimer's, Parkinson's, and stroke studies, personalized medicine focusing on patient-derived model systems, and toxicology testing requiring standardized, reproducible assay formats. These application domains influence platform selection and throughput expectations; for example, high throughput screening favors scalable, plate-compatible model formats, whereas Alzheimer's research often demands long-term culture stability and complex cellular interactions.

End users shape commercial and service models, as academia represented by research institutes and universities emphasizes exploratory innovation and protocol openness, contract research organizations prioritize turnkey service delivery and regulatory alignment, hospitals and clinics seek clinically actionable readouts integrated with patient care workflows, and pharma and biotech companies including large pharmaceutical firms and small or mid-size biotech entities focus on translational endpoints and portfolio de-risking. These distinctions determine procurement cycles, validation rigor, and willingness to invest in bespoke model development.

Technology segmentation highlights core enablers: biofabrication with 3D bioprinting supports structural complexity; microfluidics including droplet microfluidics and organ-on-chip architectures enable dynamic microenvironments; neural interfaces that span in vitro electrophysiology and in vivo recording deliver high-resolution functional data; and organoid culture approaches, both scaffold-based and scaffold-free, offer self-organizing systems that recapitulate developmental processes. Disease model segmentation concentrates efforts on Alzheimer's, epilepsy, Parkinson's, and stroke, where mechanistic understanding and unmet therapeutic need drive the creation of specialized assays and maturation protocols. Integrating these segmentation lenses allows stakeholders to map technological investments to specific application needs and end-user expectations, supporting targeted development and commercialization strategies.

Delineating regional strengths, regulatory nuances, and innovation ecosystems that determine strategic entry points and collaborative pathways across global markets

Regional dynamics are central to strategic positioning because innovation ecosystems, regulatory climates, and manufacturing capacity vary substantially across geographic markets. In the Americas, strong translational research infrastructure, dense networks of clinical trial sites, and a mature biotech financing environment support rapid progression from discovery to early clinical validation. This region also benefits from established biomanufacturing capabilities and a large pool of experienced neuroscientists, which together facilitate partnerships between industrial and academic stakeholders and the scaling of prototype platforms into validated services.

In Europe, Middle East & Africa, regulatory harmonization efforts, growing investment in specialized centers of excellence, and progressive ethical frameworks have created favorable conditions for collaborative research and public-private partnerships. Several jurisdictions emphasize standards for reproducibility and data sharing, which encourages multicenter validation studies and protocol standardization. Additionally, regional manufacturing clusters focused on precision instrumentation and microfabrication contribute to shorter supply chains for equipment and device components.

The Asia-Pacific region exhibits rapid capacity expansion driven by increasing domestic R&D investment, growing clinical trial activity, and strategic government support for advanced biotechnologies. Local talent pools in engineering and stem cell biology enable innovation in biofabrication and organoid culture methodologies. Moreover, a competitive manufacturing base offers opportunities for cost-effective production of reagents and instrumentation, although stakeholders must navigate heterogeneous regulatory regimes and variable market access pathways. Understanding these regional nuances enables organizations to align go-to-market strategies, partnership models, and supply chain design with localized strengths and constraints.

Evaluating competitive strategies, platform differentiation, partnership models, and innovation tactics that determine leadership and scalability in the sector

Competitive dynamics among companies in the human brain model space center on platform differentiation, service breadth, and the ability to demonstrate translational relevance through validation studies and external collaborations. Leading organizations emphasize modular platforms that allow customers to configure models by disease focus, analytical readout, and throughput, thereby addressing diverse research needs across academic and commercial users. Strategic alliances with academic centers and clinical consortia frequently serve as credibility-building mechanisms, enabling firms to benchmark platform performance against established biological endpoints.

Commercial strategies vary from product-centric supply of consumables and instrumentation to service-oriented models that deliver end-to-end assay execution and data interpretation. Firms that successfully combine proprietary assays with robust data pipelines and interpretive analytics create higher switching costs and foster long-term client relationships. Intellectual property strategies typically protect core platform technologies while maintaining interoperability through standardized data formats and validated interfaces, which facilitates ecosystem adoption without isolating collaborators.

In addition, companies are increasingly leveraging open innovation approaches to accelerate algorithm development and phenotypic interpretation, while selectively protecting hardware or wet-lab process innovations. Strategic M&A activity and targeted partnerships enable firms to rapidly expand geographic presence, augment technical capabilities, and gain access to clinical or regulatory expertise. For leadership teams, the imperative is to balance rapid commercialization with rigorous external validation, ensuring that service quality and scientific credibility scale in tandem with commercial ambitions.

Implementing resilient procurement, collaborative validation, modular product architectures, and cross-disciplinary talent strategies to accelerate adoption and de-risk development

Leaders should adopt a set of actionable initiatives that align technological capability with organizational objectives and market realities. First, prioritize supply chain resilience by establishing dual-sourcing strategies for critical reagents and components, qualifying regional suppliers, and creating contingency inventories to minimize disruption. This tactical shift reduces operational risk and allows R&D timelines to remain predictable despite external shocks.

Second, pursue collaborative validation programs with academic and clinical partners to accelerate platform acceptance. These programs should emphasize reproducibility, standardized endpoints, and open data-sharing agreements that preserve intellectual property while enabling independent verification. By doing so, organizations can build credibility with regulators and end users while accelerating adoption across translational pipelines.

Third, invest in modular product architectures that enable customers to combine high-throughput compatible formats with functionally mature, physiologically relevant systems. Complement hardware investments with robust software for data capture and analysis, ensuring that experimental complexity translates into actionable insights. Moreover, actively engage regulatory affairs expertise early in development to align assay qualification with anticipated submission requirements.

Finally, cultivate talent across disciplines by integrating engineers, stem cell biologists, computational scientists, and regulatory specialists into cross-functional teams. This human capital strategy fosters rapid iteration, supports method standardization, and facilitates commercialization pathways. Taken together, these recommendations offer a pragmatic roadmap for organizations seeking to convert technical promise into sustainable competitive advantage.

Describing a rigorous mixed-methods research approach integrating expert interviews, literature and patent review, technology readiness assessments, and validation workshops

The research methodology underpinning this analysis combined qualitative and quantitative approaches to ensure robustness and practical relevance. Primary research included structured interviews with a cross-section of stakeholders, encompassing senior scientists in academia, R&D leaders in pharmaceutical and biotechnology companies, heads of specialized contract research organizations, instrumentation developers, and regulatory subject-matter experts. These conversations provided insight into technology adoption drivers, validation requirements, and procurement timelines from multiple vantage points.

Secondary research involved systematic review of peer-reviewed literature, patent filings, regulatory guidance documents, technical white papers, and conference proceedings to chart the evolution of methodologies and identify emerging best practices. Technology readiness assessments were conducted to evaluate maturational trajectories for specific platforms, and patent landscaping informed competitive positioning and freedom-to-operate considerations. Data triangulation methods reconciled disparate inputs and highlighted consensus areas as well as persistent gaps requiring further investigation.

To ensure analytical transparency, findings were validated through advisory workshops with external experts and cross-checked against available protocol repositories and reproducibility studies. Limitations were acknowledged where proprietary data remained inaccessible or where nascent technologies lacked long-term validation records. Ethical compliance was integral throughout the research process, with interview protocols and data handling designed to preserve confidentiality and respect intellectual property boundaries.

Synthesizing strategic imperatives and operational priorities that determine which organizations will translate human brain model innovation into sustainable clinical and commercial value

In conclusion, human brain models represent a transformative set of tools that are reshaping how neuroscience questions are addressed and how therapeutic strategies are de-risked prior to clinical development. The field is characterized by rapid technological convergence, evolving regulatory expectations, and shifting commercial models that reward demonstrable translational relevance. Stakeholders who invest in validation, interoperability, and supply chain resilience will be best positioned to translate platform advances into clinically meaningful outcomes.

Strategic choices made today-around platform modularity, partnership structures, regional engagement, and talent acquisition-will determine which organizations capture long-term value as the ecosystem matures. While challenges remain, including standardization, reproducibility, and regulatory alignment, the cumulative progress across biofabrication, organoid culture, microfluidics, and computational modeling creates a coherent pathway toward more predictive and human-relevant research systems. As adoption spreads, success will hinge on cross-sector collaboration, disciplined operational execution, and a consistent focus on scientifically rigorous validation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Brain Models Market, by Disease Model

  • 8.1. Alzheimer's
  • 8.2. Epilepsy
  • 8.3. Parkinson's
  • 8.4. Stroke

9. Human Brain Models Market, by Technology

  • 9.1. Biofabrication
  • 9.2. Microfluidics
    • 9.2.1. Droplet Microfluidics
    • 9.2.2. Organ-on-Chip
  • 9.3. Neural Interface
    • 9.3.1. In Vitro Electrophysiology
    • 9.3.2. In Vivo Recording
  • 9.4. Organoid Culture
    • 9.4.1. Scaffold-Based
    • 9.4.2. Scaffold-Free

10. Human Brain Models Market, by Application

  • 10.1. Drug Discovery
    • 10.1.1. High Throughput Screening
    • 10.1.2. Lead Optimization
  • 10.2. Neuroscience Research
    • 10.2.1. Alzheimer's Research
    • 10.2.2. Parkinson's Research
    • 10.2.3. Stroke Studies
  • 10.3. Personalized Medicine
  • 10.4. Toxicology Testing

11. Human Brain Models Market, by End User

  • 11.1. Academia
    • 11.1.1. Research Institutes
    • 11.1.2. Universities
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Clinics
  • 11.4. Pharma & Biotech
    • 11.4.1. Large Pharma
    • 11.4.2. Small & Mid-Size Biotech

12. Human Brain Models Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Brain Models Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Brain Models Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Human Brain Models Market

16. China Human Brain Models Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 3D Systems, Inc.
  • 17.6. Anatomy Warehouse, LLC
  • 17.7. Brainlab AG
  • 17.8. EISCO Scientific
  • 17.9. ESP Models
  • 17.10. GE HealthCare Technologies Inc.
  • 17.11. Global Plastics, Inc.
  • 17.12. GPI Anatomicals
  • 17.13. Koninklijke Philips N.V.
  • 17.14. Materialise NV
  • 17.15. Medtronic plc
  • 17.16. Organovo Holdings, Inc.
  • 17.17. Scientific Accessories, Inc.
  • 17.18. Siemens Healthineers AG
  • 17.19. SmartLabs Education Ltd.
  • 17.20. Stratasys Ltd.
  • 17.21. Stryker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN BRAIN MODELS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN BRAIN MODELS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY BIOFABRICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY BIOFABRICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY BIOFABRICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DROPLET MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DROPLET MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DROPLET MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGAN-ON-CHIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGAN-ON-CHIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGAN-ON-CHIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VITRO ELECTROPHYSIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VITRO ELECTROPHYSIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VITRO ELECTROPHYSIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VIVO RECORDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VIVO RECORDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY IN VIVO RECORDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SCAFFOLD-FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ALZHEIMER'S RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PARKINSON'S RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY STROKE STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY TOXICOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY TOXICOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SMALL & MID-SIZE BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SMALL & MID-SIZE BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY SMALL & MID-SIZE BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 216. GCC HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 218. GCC HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 222. GCC HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. GCC HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 225. GCC HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. GCC HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 227. GCC HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 252. G7 HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 254. G7 HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 256. G7 HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 258. G7 HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. G7 HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 261. G7 HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. G7 HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 263. G7 HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 264. NATO HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 266. NATO HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 269. NATO HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 270. NATO HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. NATO HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 273. NATO HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. NATO HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 275. NATO HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL HUMAN BRAIN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA HUMAN BRAIN MODELS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY DISEASE MODEL, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY MICROFLUIDICS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY NEURAL INTERFACE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY ORGANOID CULTURE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY NEUROSCIENCE RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY ACADEMIA, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA HUMAN BRAIN MODELS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)